Table 2.
Characteristics of the 74 subjects included in the STOP Pain Project and efficacy and safety parameters according to IL6 G174C, G572C, and A597G polymorphisms.
| IL-6 rs1800795 | p-Value | IL-6 rs1800796 | p-Value | IL-6 rs1800797 | p-Value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| G/G | G/C | CC | G/G | G/C | A/A | A/G | G/G | ||||
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | ||||
| 35 | 30 | 9 | 63 | 11 | 8 | 29 | 37 | ||||
| Gender | |||||||||||
| Male | 17 (48.57) | 18 (60.00) | 5 (55.56) | 0.683 * | 36 (57.14) | 4 (36.36) | 0.326 * | 6 (75.00) | 16 (55.17) | 18 (48.65) | 0.399 * |
| Female | 18 (51.43) | 12 (40.00) | 4 (44.44) | 27 (42.86) | 7 (63.64) | 2 (25.00) | 13 (44.83) | 19 (51.35) | |||
| Age (months) | |||||||||||
| 0–36 | 14 (40.00) | 5 (16.67) | 2 (22.22) | 0.156 * | 18 (28.57) | 3 (27.27) | 1.000 * | 2 (25.00) | 6 (20.69) | 13 (35.14) | 0.542 * |
| >36–144 | 9 (25.71) | 15 (50.00) | 5 (55.56) | 25 (39.68) | 4 (36.36) | 4 (50.00) | 14 (48.28) | 11 (29.73) | |||
| >144 | 12 (34.29) | 10 (33.33) | 2 (22.22) | 20 (31.75) | 4 (36.36) | 2 (25.00) | 9 (31.03) | 13 (35.14) | |||
| BMI (percentile) | |||||||||||
| <25th | 11 (31.43) | 11 (36.67) | 2 (22.22) | 0.752 * | 21 (33.33) | 3 (27.27) | 0.886 * | 1 (12.50) | 11 (37.93) | 12 (32.43) | 0.607 * |
| 25th–75th | 7 (20.00) | 4 (13.33) | 3 (33.33) | 11 (17.46) | 3 (27.7) | 3 (37.50) | 3 (10.34) | 8 (21.62) | |||
| ≥75th | 9 (25.71) | 11 (36.67) | 3 (33.33) | 20 (31.75) | 3 (27.27) | 3 (37.50) | 10 (34.48) | 10 (27.03) | |||
| Missing | 8 (22.86) | 4 (13.33) | 1 (11.11) | 11 (17.46) | 2 (18.18) | 1 (12.50) | 5 (17.24) | 7 (18.92) | |||
| Diagnosis | |||||||||||
| Brain Tumor | 4 (11.43) | - | - | 0.299 * | 2 (3.17) | 2 (18.18) | 0.433 * | - | - | 4 (10.81) | 0.171 * |
| Histiocytosis | 3 (8.57) | 1 (3.33) | - | 4 (6.35) | - | - | 1 (3.45) | 3 (8.11) | |||
| Leukemia and Lymphoma |
10 (28.57) | 15 (50.00) | 6 (66.67) | 25 (39.68) | 6 (54.55) | 6 (75.00) | 15 (51.72) | 10 (27.03) | |||
| Neuroblastoma | 5 (14.29) | 1 (3.33) | - | 6 (9.52) | - | - | 2 (6.90) | 4 (10.81) | |||
| Osteosarcoma | 6 (17.14) | 5 (16.67) | 2 (22.22) | 11 (17.46) | 2 (18.18) | 2 (25.00) | 3 (10.34) | 8 (21.62) | |||
| Sarcoma | 7 (20.00) | 6 (20.00) | 1 (11.11) | 13 (20.63) | 1 (9.09) | - | 6 (20.69) | 8 (21.62) | |||
| Other | - | 2 (6.67) | - | 2 (3.17) | - | - | 2 (6.90) | - | |||
| Metastasis | |||||||||||
| No | 24 (68.57) | 22 (73.33) | 7 (77.78) | 0.878 * | 45 (71.43) | 8 (72.73) | 1.000 * | 7 (87.50) | 23 (79.31) | 23 (62.16) | 0.222 * |
| Yes | 11 (31.43) | 8 (26.67) | 2 (22.22) | 18 (28.57) | 3 (27.27) | 1 (12.50) | 6 (20.69) | 14 (37.84) | |||
| Pain location | |||||||||||
| Abdominal | 7 (20.00) | 3 (10.00) | 1 (11.11) | 0.834 * | 9 (14.29) | 2 (18.18) | 0.728 * | 1 (12.50) | 2 (6.90) | 8 (21.62) | 0.537 * |
| Oral cavity | 17 (48.57) | 16 (53.33) | 4 (44.44) | 30 (47.62) | 7 (63.64) | 5 (62.50) | 15 (51.72) | 17 (45.95) | |||
| Skeletal–Muscle | 3 (8.57) | 5 (16.67) | 2 (22.22) | 9 (14.29) | 1 (9.09) | 1 (12.50) | 6 (20.69) | 3 (8.11) | |||
| Other | 8 (22.86) | 6 (20.00) | 2 (22.22) | 15 (23.81) | 1 (9.09) | 1 (12.50) | 6 (20.69) | 9 (24.32) | |||
| Pain Intensity PIt0 | |||||||||||
| Mean ± SD Median (IQ Range) |
4.86 ± 2.315 5 (3–7) |
3.97 ± 1.810 4 (3–5) |
3.44 ± 2.186 3 (2–5) |
0.104 ** 0.223 † |
4.40 ± 2.189 4 (3–6) |
3.91 ± 1.921 4 (3–5) |
0.490 ** 0.434 † |
3.12 ± 2.100 3 (1.5–5) |
3.79 ± 1.800 4 (3–5) |
5 ± 2.224 5 (3–7) |
0.017 ** 0.040 † |
| Pain Intensity PIto Grouped |
|||||||||||
| ≤4 | 17 (48.57) | 18 (60.00) | 5 (55.56) | 0.683 * | 32 (50.79) | 8 (72.73) | 0.208 * | 5 (62.50) | 19 (65.52) | 16 (43.24) | 0.196 * |
| >4 | 18 (51.43) | 12 (40.00) | 4 (44.44) | 31 (49.21) | 3 (27.27) | 3 (37.50) | 10 (34.48) | 21 (56.76) | |||
| Drug | |||||||||||
| Morphine | 25 (71.43) | 21 (70.00) | 5 (55.56) | 0.610 * | 42 (66.67) | 9 (81.82) | 0.387 * | 4 (50.00) | 20 (68.97) | 27 (72.97) | 0.452 * |
| Tramadol | 7 (20.00) | 6 (20.00) | 4 (44.44) | 16 (25.40) | 1 (9.09) | 4 (50.00) | 6 (20.69) | 7 (18.92) | |||
| Oxycodone | 1 (2.86) | - | - | 1 (1.59) | - | - | - | 1 (2.70) | |||
| Codeine | - | 2 (6.67) | - | 1 (1.59) | 1 (9.09) | - | 2 (6.90) | - | |||
| more than one | 2 (5.71) | 1 (3.33) | - | 3 (4.76) | - | - | 1 (3.45) | 2 (5.41) | |||
* Fisher’s exact test. † Kruskal–Wallis test. ** ANOVA.